Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Core Viewpoint - The Africa CDC is leading a pan-African clinical trial, MOSA, to evaluate therapeutic options for Mpox, addressing a significant health threat across the continent, particularly in vulnerable populations [1][2][5]. Group 1: Clinical Trial Details - The MOSA trial has commenced patient enrollment at Mbandaka Hospital in the DRC, marking a pivotal step in combating the Mpox health threat [1]. - The trial will assess the safety and efficacy of brincidofovir, an antiviral from Emergent BioSolutions, administered in a liquid oral formulation [3]. - A first interim analysis of the trial is anticipated by the end of Q1 2025 [4]. Group 2: Health Threat Context - Mpox was declared a Public Health Emergency of Continental Security on August 13, 2024, and remains a significant health threat, especially among women, children, and individuals living with HIV [2]. - No therapeutic has been approved for Mpox treatment in the U.S. or Africa, highlighting the urgent need for effective treatment options [2]. Group 3: Research and Development Leadership - The MOSA trial exemplifies Africa's leadership in addressing healthcare gaps, with support from the European Union's Horizon Europe program [5][6]. - The study design includes pre-planned interim analyses to facilitate rapid decision-making based on early trial results [5]. - PANTHER, a key research partner, aims to contribute to the response to the Mpox crisis while preparing for future health emergencies [7]. Group 4: Broader Implications - The ongoing research efforts, including the MOSA trial, are part of a larger initiative to advance treatments and vaccines for Mpox, which continues to pose a global public health threat [9]. - The collaboration among African and global researchers through platforms like PANTHER is crucial for enhancing pandemic preparedness and response [11].